AMAG shareholders to receive rights to purchase shares under Rights Plan

NewsGuard 100/100 Score

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its Board of Directors has adopted a Shareholder Rights Plan (“Rights Plan”) under which all shareholders of record as of September 17, 2009 will receive rights to purchase shares of a new series of Preferred Stock.

The Rights Plan is designed to ensure that all AMAG shareholders receive fair and equal treatment in the event that an unsolicited attempt is made to acquire AMAG. The Rights Plan has not been adopted in response to any specific proposal. It is intended to provide the Board of Directors with sufficient time to evaluate alternatives and to maximize value to shareholders.

Under the Rights Plan, the Board of Directors declared a non-taxable dividend of one Right for each outstanding share of AMAG Common Stock to shareholders of record as of the close of business on September 17, 2009. Initially, these Rights will not be exercisable and will trade with the shares of AMAG Common Stock. The Rights will be exercisable only if a person or group acquires 20% or more of AMAG’s Common Stock or announces a tender offer for 20% or more of AMAG’s Common Stock. Once exercisable, each Right will entitle the holder to purchase from AMAG one one-thousandth of a share of Preferred Stock.

If a person or group acquires 20% or more of AMAG’s Common Stock (an “Acquiring Person”), then each holder of a Right (other than the Acquiring Person or group) would be entitled to purchase, at the exercise price of the Right, such number of shares of AMAG Common Stock having a current value of twice the exercise price of the Right. In addition, if a person or group becomes an Acquiring Person, then until such Acquiring Person acquires 50% or more of AMAG’s Common Stock, the Board of Directors can exchange Rights, in part or in whole, for AMAG Common Stock. If AMAG is acquired in a merger or other business combination transaction, each holder of a Right (other than the Acquiring Person or group) would then be entitled to purchase, at the exercise price of the Right, such number of shares of the acquiring company’s common stock having a current value of twice the exercise price of the Right. The Board of Directors may redeem the Rights or terminate the Rights Plan at any time before a person or group becomes an Acquiring Person. The Rights will expire on September 17, 2019, ten years from the record date.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rethinking exercise in post-COVID care